Lifeboat Foundation

Houston, TX — Oct 8, 2020 - In a letter published today in the New England Journal of Medicine, a team of physicians from Baylor College of Medicine, Texas Children’s Hospital, and the University of California, San Francisco, describe a remarkable case of a Type 1 diabetes (T1D) patient, who no longer needs insulin to maintain optimal blood sugar levels. The physicians employed a precision/personalized medicine approach to specifically target the underlying genetic mutation, which was the primary driver of this patient’s diabetes.

“To the best of our knowledge, this is the first example of a T1D patient who has experienced a complete reversal of insulin-dependence and we are excited by the prospect that that could be a viable therapeutic strategy for a subset of T1D patients” said corresponding author Dr. Lisa R. Forbes, deputy director for clinical services and community outreach for the Texas Children’s William T. Shearer Center for Human Immunobiology and assistant professor of Pediatrics, Immunology, Allergy and Retrovirology at Baylor.

T1D is a chronic condition in which the pancreas produces little to no insulin, a hormone that maintains sugar levels in the blood. Currently, the treatment options available to T1D patients consist of managing blood sugar levels with insulin, diet and exercise to prevent further complications.

Researchers at the Indian Institute of Technology Bhubaneswar, in collaboration with TCS Research and Wageningen University, recently devised a new strategy that could improve coordination among different robots tackling complex missions as a team. This strategy, introduced in a paper pre-published on arXiv, is based on a split-architecture that addresses communication and computations separately, while periodically coordinating the two to achieve optimal results.

The researchers’ paper was recently presented at the IEEE RoboCom 2022 conference, held in conjunction with IEEE CCNC 2022, a top tier conference in the field of networking and distributed computing. At IEEE RoboCom 2022, it received the Best Paper Award.

“Swarm-robotics is on the path to becoming a key tool for human civilization,” Dr. Sudipta Saha, the lead researcher of the team that carried out the study, told TechXplore. “For instance, in medical science, it will be necessary to use numerous nano-bots to boost immune-therapy, targeted and effective drug transfer, etc.; while in the army it will be necessary for exploring unknown terrains that are hard for humans to enter, enabling agile supervision of borders and similar activities. In construction, it can enable technologies such as large-scale 3D printing and in agriculture it can help to monitor crop health and intervene to improve yields.”

Even in people with signs of Alzheimer’s and other dementia, a new study found exercise boosted proteins in the brain that may prevent cognitive decline.

Chief information security officers’ (CISOs) greatest challenge going into 2022 is countering the speed and severity of cyberattacks. The latest real-time monitoring and detection technologies improve the odds of thwarting an attack but aren’t foolproof. CISOs tell VentureBeat that bad actors avoid detection with first-line monitoring systems by modifying attacks on the fly. That’s cause for concern, especially with CISOs in financial services and health care.

Enterprises are in react mode

Enterprises fail to get the most value from threat monitoring, detection, and response cybersecurity strategies because they’re too focused on data collection and security monitoring alone. CISOs tell VentureBeat they’re capturing more telemetry (i.e., remote) data than ever, yet are short-staffed when it comes to deciphering it, which means they’re often in react mode.

Our gut microbiome helps us out every day by processing the fiber we can’t digest. The bacteria ferment the fiber into key chemicals known as short-chain fatty acids, or SCFAs, that are essential for human health. SCFAs fight inflammation, help kill dangerous bacteria, protect the lining of the gut, and can even help prevent cancer.

In a new study, the John Denu lab at the University of Wisconsin-Madison’s Wisconsin Institute for Discovery has learned that the fatty acids butyrate and propionate also activate p300, a crucial human enzyme that promotes the unspooling of DNA. This unwound DNA allows more genes to become active and expressed, which ultimately affects human health.

A study by Wisconsin Institute for Discovery researchers challenges long-held beliefs, with potential implications for physiological processes and diseases such as propionic acidemia, autism spectrum disorder and Alzheimer’s disease.

Movano has unveiled its new smart ring, which can track steps, sleep, heart rate, heart rate variability, and several other important health metrics.

Exercise for weight loss and its link to long life is explored in new research. Exercise carries many health benefits, independent of how much weight loss occurs.

Hackers breached the computer networks of a southeast Florida health care system in October and may have accessed sensitive personal and financial information on over 1.3 million people, the health care system announced this week.

Social Security numbers, patient medical history and bank account information are among the data that have been exposed in the breach of Broward Health, a network of over 30 health care facilities serving patients across roughly 2 million-person Broward County, Florida, according to a notice the health care provider filed with the Office of the Maine Attorney General.

About 470 of the data breach victims live in Maine. Like other states, Maine law requires organizations that hold state residents’ personal data to file a disclosure when they’ve been hacked.

A cheap, widely available drug used to treat mental illness cuts both the risk of death from COVID-19 and the need for people with the disease to receive intensive medical care, according to clinical-trial results1. The drug, called fluvoxamine, is taken for conditions including depression and obsessive-compulsive disorder. But it is also known to dampen immune responses and temper tissue damage, and researchers credit these properties with its success in the recent trial. Among study participants who took the drug as directed and did so in the early stages of the disease, COVID-19-related deaths fell by roughly 90% and the need for intensive COVID-19-related medical care fell by roughly 65%.

Study co-author Angela Reiersen, a psychiatrist at Washington University School of Medicine in St Louis, Missouri, has long been interested in using fluvoxamine to treat a rare genetic condition. While monitoring the fluvoxamine literature before the pandemic, she came across a 2019 study showing that fluvoxamine reduced inflammation in mice with sepsis². When COVID-19 hit, “I immediately thought back to that paper with the mice,” she says.

Reiersen and her colleagues partnered with the organizers of the TOGETHER Trial, which aims to identify approved drugs that can be repurposed to treat COVID-19. The team’s study included 1,497 people in Brazil who had COVID-19 and were at high risk of severe disease. Roughly half received fluvoxamine, and the rest received a placebo.

Continue reading “Common antidepressant slashes risk of COVID death, study says” »